头孢洛林对需氧革兰氏阳性和革兰氏阴性病原菌的活性：检测方法变异性的影响
Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability.
作者信息
Citron Diane M, Warren Yumi A, Tyrrell Kerin L, Goldstein Ellie J C
机构信息
R.M. Alden Research Laboratory, Culver City, CA 90230, USA.
出版信息
ISRN Microbiol. 2011 Nov 17;2011:787290. doi: 10.5402/2011/787290. Print 2011.
Abstract
Ceftaroline is a new cephalosporin with bactericidal activity against methicillin-resistant S. aureus (MRSA) as well as gram-negative pathogens. Variations of in vitro test conditions were found to affect ceftaroline activity, with 5% NaCl inhibiting growth and/or reducing the minimum inhibitory concentrations (MICs) for E. coli, K. pneumoniae, M. catarrhalis, H. influenzae, and streptococci, while an inoculum of 10(6) CFU/mL raised MICs of some E. coli, K. pneumoniae, and M. catarrhalis strains.
摘要
头孢洛林是一种新型头孢菌素，对耐甲氧西林金黄色葡萄球菌（MRSA）以及革兰氏阴性病原体具有杀菌活性。发现体外试验条件的变化会影响头孢洛林的活性，5%氯化钠会抑制大肠杆菌、肺炎克雷伯菌、卡他莫拉菌、流感嗜血杆菌和链球菌的生长和/或降低其最低抑菌浓度（MIC），而接种量为10(6) CFU/mL会提高某些大肠杆菌、肺炎克雷伯菌和卡他莫拉菌菌株的MIC。
相似文献
1
Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability.头孢洛林对需氧革兰氏阳性和革兰氏阴性病原菌的活性：检测方法变异性的影响
ISRN Microbiol. 2011 Nov 17;2011:787290. doi: 10.5402/2011/787290. Print 2011.
2
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.头孢洛林（PPI-0903M，T-91825）对具有明确耐药机制和表型的细菌的体外活性。
J Antimicrob Chemother. 2007 Aug;60(2):300-11. doi: 10.1093/jac/dkm150. Epub 2007 Jun 4.
3
Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.革兰阳性菌和革兰阴性菌中头孢洛林多步耐药发展研究。
Antimicrob Agents Chemother. 2011 May;55(5):2344-51. doi: 10.1128/AAC.01602-10. Epub 2011 Feb 22.
4
Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.新型头孢菌素头孢洛林对社区获得性肺炎患者血培养分离菌的活性
Int J Antimicrob Agents. 2009 Jun;33(6):515-9. doi: 10.1016/j.ijantimicag.2008.12.005. Epub 2009 Feb 8.
5
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.头孢洛林酯治疗社区获得性细菌性肺炎和急性细菌性皮肤和皮肤结构感染。
Drugs. 2012 Jul 30;72(11):1473-93. doi: 10.2165/11635660-000000000-00000.
6
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.AWARE 头孢洛林监测计划（2008-2010 年）：美国肺炎链球菌、流感嗜血杆菌和卡他莫拉菌耐药模式的趋势。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S187-93. doi: 10.1093/cid/cis561.
7
In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.2010 年至 2012 年加拿大医院分离的革兰阴性和革兰阳性病原菌的体外研究：来自 CANWARD 监测研究的结果。
Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.
8
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.比较头孢洛林对与社区获得性肺炎相关病原体的活性：一项国际监测研究的结果。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii69-80. doi: 10.1093/jac/dkr101.
9
In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.2009 年加拿大医院分离的革兰阳性和革兰阴性病原菌的体外 ceftaroline 活性。
Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.
10
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).检测亚太地区和南非分离的致皮肤软组织感染和社区获得性呼吸道感染的细菌分离株的抗菌活性：头孢洛林和比较剂（2010 年）。
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8. doi: 10.1016/j.diagmicrobio.2013.01.005. Epub 2013 Mar 25.
本文引用的文献
1
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.头孢洛林酯，一种用于潜在治疗耐甲氧西林金黄色葡萄球菌感染的头孢菌素衍生物。
Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.
2
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.头孢洛林和ME1036对社区获得性耐甲氧西林金黄色葡萄球菌临床分离株的抗菌活性。
Antimicrob Agents Chemother. 2008 Mar;52(3):1153-5. doi: 10.1128/AAC.01351-07. Epub 2008 Jan 7.
3
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.头孢洛林对比标准疗法治疗复杂性皮肤及皮肤结构感染的2期研究
Antimicrob Agents Chemother. 2007 Oct;51(10):3612-6. doi: 10.1128/AAC.00590-07. Epub 2007 Aug 6.
4
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.在兔心内膜炎模型中，新型广谱头孢菌素头孢洛林（PPI-0903）与利奈唑胺和万古霉素相比，对耐甲氧西林和万古霉素中介金黄色葡萄球菌的体内疗效。
Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25.
5
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.头孢洛林（PPI-0903M，T-91825）对具有明确耐药机制和表型的细菌的体外活性。
J Antimicrob Chemother. 2007 Aug;60(2):300-11. doi: 10.1093/jac/dkm150. Epub 2007 Jun 4.
6
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.新型头孢菌素PPI - 0903M（T91825）的评估：杀菌活性、体外测试参数修改的影响及纸片扩散法测试的优化
J Antimicrob Chemother. 2005 Dec;56(6):1047-52. doi: 10.1093/jac/dki362. Epub 2005 Oct 20.
7
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.新型头孢菌素PPI-0903M（T-91825）对全球临床分离菌株的抗菌活性及抗菌谱
Antimicrob Agents Chemother. 2005 Aug;49(8):3501-12. doi: 10.1128/AAC.49.8.3501-3512.2005.
Zotero 插件